ArticleCureus2025
Second Primary Malignancies and Their Associations With Age, Gender, and Latency Periods in Urogenital Cancers: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to identify the sites and risks of developing second primary malignancies (SPMs) after urogenital cancers, as well as their associations with race, gender, and age.
methodsThis was a retrospective cohort study involving 140,620 subjects with primary urogenital cancer. The data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database, covering the duration from January 1975 to April 2025. This study included only those patients who were diagnosed with primary urogenital cancer. Descriptive statistics, absolute excess risk (AER), and observed-to-expected ratios (O/E) were calculated.
resultsOut of the 140,620 patients observed, 106,377 (75.64%) were male. Among the patients diagnosed with urogenital cancer, 33,680 (23.9%) developed an SPM. The mean age for the development of an SPM was 75.12 years. The risk of developing an SPM in patients with urogenital cancer was significantly higher compared to the general population (O/E = 1.31, confidence interval (CI) = 1.30-1.33, AER = 67.83). Male genital system cancers (O/E = 1.27, CI = 1.24-1.30, AER = 13.41), respiratory system cancers (O/E = 1.75, CI = 1.71-1.80, AER = 26.02), and urinary system cancers (O/E = 2.28, CI = 2.22-2.33, AER = 29.16) were among the most commonly identified SPMs. A total of 17,869 (53%) patients with an SPM belonged to the >75 years age group.
conclusionCompared to the general population, patients with urogenital cancer had a considerably higher risk of developing an SPM. Most SPM cases were observed in individuals aged 50-74 years and those over 75. A latency period of 12-59 months was commonly noted before the development of an SPM. The most frequently reported SPMs involved the male genital, respiratory, and urinary systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.